Proximal DVT · people requiring prevention of venous thromboembolism
1 finding from 1 review
Proximal DVT · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower proximal DVT compared with placebo (moderate certainty).
1 finding from 1 review
Total PE · people requiring prevention of venous thromboembolism
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
1 finding from 1 review
All causes of death · people requiring prevention of venous thromboembolism
1 finding from 1 review
Total PE · people requiring prevention of venous thromboembolism
Fondaparinux leads to lower total PE compared with placebo (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to higher major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
All causes of death · people requiring prevention of venous thromboembolism
Fondaparinux showed no clear difference in all causes of death compared with placebo (moderate certainty).
1 finding from 1 review
Total VTE · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower total VTE compared with LMWH (moderate certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism
Fondaparinux showed no clear difference in symptomatic VTE compared with LMWH (moderate certainty).
1 finding from 1 review
Pain‐free walking distance · people with symptomatic intermittent claudication
1 finding from 1 review
Change in maximum walking distance (MWD) · people with symptomatic intermittent claudication
1 finding from 1 review
Final value MWD · people with symptomatic intermittent claudication
1 finding from 1 review
Adverse effects · people with symptomatic intermittent claudication
It is very uncertain whether padma 28 changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Ankle brachial index · people with symptomatic intermittent claudication
1 finding from 1 review
ABI ‐ change from baseline · people with symptomatic intermittent claudication
1 finding from 1 review
Therapeutic INR INR TEST · patients with venous thromboembolism.
10 mg warfarin nomogram probably leads to higher therapeutic INR INR TEST compared with 5 mg warfarin nomogram (moderate certainty).
1 finding from 1 review
Recurrent venous thromboembolism · patients with venous thromboembolism.
10 mg warfarin nomogram showed no clear difference in recurrent venous thromboembolism sonography or lung scan or chest… compared with 5 mg warfarin nomogram (low certainty).
1 finding from 1 review
Major bleeding fall in hemoglobin of > 20 g/L or transfusion of 2 or more units of red cells · patients with venous thromboembolism.
10 mg warfarin nomogram showed no clear difference in major bleeding fall in hemoglobin of > 20 g/L or transfusion of 2 or… compared with 5 mg warfarin nomogram (moderate certainty).
1 finding from 1 review
Minor bleeding · patients with venous thromboembolism.
It is very uncertain whether 10 mg warfarin nomogram changes minor bleeding it is not major bleeding compared with 5 mg warfarin nomogram (very low certainty).
1 finding from 1 review